About BrainStorm Cell
BrainStorm Cell is a publicly listed company based in Petah Tikva (Israel) founded in 2000. It operates as a developer ofstem cell therapies for the treatment of neurodegenerative diseases such as ALS, MS, PD. The company has 27 employees. Its chief executive is Chaim Lebovits. BrainStorm Cell offers products and services including NurOwn. Its focus areas include Life Sciences, Cell Therapy, Stem Cells and Progenitor Cells. Its legal entity is BRAINSTORM CELL THERAPEUTICS INC. Its competitors include Mesoblast, RoosterBio, SanBio, Osiris and SCM Lifescience and 4 more; 6 of its 9 listed competitors have raised funding.
Company details
BrainStorm Cell Therapeutics was founded in 2000 in Petah Tikva, Israel, within the biotechnology sector. Autologous stem cell therapies are developed for neurodegenerative disorders such as ALS, multiple sclerosis, and Parkinsons disease. The NurOwn platform is utilized to differentiate mesenchymal stem cells into neurotrophic factor-secreting cells for transplantation near affected sites. Animal models of these diseases, including Huntingtons and peripheral nerve injury, are employed in research and testing.
- Headquarters Petah Tikva, Israel
- Employees 27
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website brainstorm-cell.com
- Social LinkedIn X Facebook
- Legal Name Brainstorm Cell Therapeutics Inc.
- Net Profit-$10.31 M (USD)11.32as on Dec 31, 2025
- EBITDA-$9.75 M (USD)14.83as on Dec 31, 2025
- Latest Funding Round$1M (USD), Post-IPO
Feb 2026
- InvestorsNational MS Society
& 4 more
- Employee Count27
Products & Services of BrainStorm Cell
BrainStorm Cell offers a comprehensive portfolio of products and services, including NurOwn.
Investigational platform for producing autologous MSC-NTF cells for neurodegenerative diseases.
Funding Insights of BrainStorm Cell
- Total Rounds 10
- Last Round Post-IPO — $1M
- First Round $206,910
(Jul 2012)
- Investors Count 5
All 10 funding rounds of BrainStorm Cell with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2026 | $1M | Post-IPO | – | – | – |
| Jun 2020 | $500,000 | Grant | – | – | |
| Apr 2020 | $1.5M | Grant | – | – | |
| Nov 2019 | $495,330 | Grant | – | – | |
| Jan 2015 | $13.3M | Debt – Conventional | – | – | – |
| Jul 2014 | $5M | Grant | – | – | |
| Jun 2014 | $10.5M | Post-IPO | – | – | – |
| May 2014 | $1.63M | Post-IPO | – | – | – |
| Dec 2013 | $800,000 | Grant | – | – | – |
| Jul 2012 | $206,910 | Post-IPO | – | – | – |
5 investors in total: 5 institutional.
Investors in BrainStorm Cell
BrainStorm Cell has secured backing from 5 investors, including institutional investors. Prominent investors backing the company include National MS Society, Israel Innovation Authority and I AM ALS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
A non-profit organization focused on ALS support and advocacy is operated. | – | iamals.org | Washington DC, United States | |
- | – | alsa.org | - | |
Business development in Israel is supported by a government organization. | 1965 | matimop.org.il | Jerusalem, Israel | |
Foundation fund focused on the eradication of multiple sclerosis | 1946 | nationalmssociety.org | Denver, United States | |
- | – | portalsaude.saude.gov.br | - |
Investor details for BrainStorm Cell
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of BrainStorm Cell
16 people are tracked at BrainStorm Cell (6 in leadership, 1 in board & advisors, 9 in team); the tracked headcount is 27.
| Name | Role | Group |
|---|---|---|
Chaim Lebovits | CEO | Leadership |
Uri Yablonka | EVP, Chief Business Officer | Leadership |
Revital Aricha | VP Research & Development | Leadership |
Bob Dagher | Executive Vice President & Chief Medical Officer | Leadership |
Haro Hartounian | Chief Operating Officer | Leadership |
Arturo Araya | Chief Commercial Officer | Leadership |
Stacy Lindborg | Board Member | Board & advisors |
Alex Burshtein | Quality Assurance Manager | Team |
Keren Mizrahi | Senior Scientist | Team |
Netta Blondheim Shraga | SVP R&d | Team |
Annael Hayun | Quality Control Associate At Brainstorm Cell Therapeutics. | Team |
Katia Lejnev | Process Development Manager | Team |
Sharon Buchler | Office Manager | Team |
Haggai Kaspi | Pre-clinical Research Manager | Team |
Yossef Levy | Qualified Person (qp) | Team |
Hamutal Nezer | Manufacturing Technician & QC | Team |
Complete people profiles for BrainStorm Cell
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of BrainStorm Cell
BrainStorm Cell is a publicly listed company on the OTC with ticker symbol BCLI in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date08 Sep 2003
- Listed onNASDAQ: BCLI
- Listed entityBrainStorm Cell Therapeutics Inc.
- Exchange sectorHealth technology
- ISINUS10501E3009
- Share price$0.83 (-2.35% on the day) · 2026-10-13
- Market capitalisation$9.2M
- EPS (diluted, trailing year)$-0.95
- Volume (last session)24,364
Financials of BrainStorm Cell
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | – | -$10.3M | -$9.8M |
| 2024 | – | -$11.6M | -$11.4M |
| 2023 | – | -$17.2M | -$21.2M |
| 2022 | – | -$24.3M | -$24.5M |
| 2021 | – | -$24.5M | -$24.3M |
Detailed financial statements for BrainStorm Cell
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of BrainStorm Cell
4 dated milestones of BrainStorm Cell across 26 years, from founding to its latest funding, stage changes and deals.
- Founded BrainStorm Cell is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $207K.
- Funding Latest funding round, Post-IPO, of $1.0M.
Competitors of BrainStorm Cell
BrainStorm Cell has 9 listed competitors in our database, 6 of them funded. They include Mesoblast, RoosterBio, SanBio, Osiris and SCM Lifescience, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| mesoblast.com | 2004 | Melbourne, Australia | – | – | Biotherapeutics derived from proprietary adult stem cell-based technologies | |
| roosterbio.com | 2012 | Frederick, United States | $38.41M | 69 | Developer of human mesenchymal stem cells and extracellular vesicles | |
| sanbio.com | 2001 | Tokyo, Japan | – | – | Regenerative cell medicines for neurological disorders are developed. | |
| osiris.com | 1992 | Baltimore, United States | – | 356 | Stem cell-based regenerative medicines are developed and marketed. | |
| scmlifescience.com | 2014 | Incheon, South Korea | $4.8M | – | Mesenchymal stem cells are developed for therapeutics using proprietary methods. | |
| cellbiomedgroup.com | 2001 | Cupertino, United States | $120M | – | Cellular therapeutics are developed for cancer, orthopaedics, and COPD. | |
| secretometherapeutics.com | 2018 | Dallas, United States | $21.9M | – | Cell-based therapies for multiple diseases are developed. | |
| stempeutics.com | 2006 | Bengaluru, India | $47.3M | 17 | Stem-cell-based products are developed for osteoarthritis and Buerger's disease. | |
| aldagen.com | 2001 | Durham, United States | $61.53M | 18 | Regenerative cell therapies for vascular disorders |
Detailed competitors of BrainStorm Cell
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of BrainStorm Cell
The website of BrainStorm Cell (brainstorm-cell.com) receives about 4.5K visits a month and ranks #4,620,847 among all websites worldwide, #5,511 in Biotechnology and Pharmaceuticals.
- Monthly visits4.5K
▲ 13.4% vs previous month
- Unique visitors1.8K
per month
- Global rank#4,620,847
among all websites
- Category rank#5,511
Health · Biotechnology and Pharmaceuticals
- Bounce rate41%
- Pages per visit1.6
- Average visit8 sec
- DevicesDesktop 42% · Mobile 58%
Websites whose visitors overlap most with BrainStorm Cell. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
neuralstem.com | neuralstem.com | 100% | – | – | – |
| scynexis.com | 99% | 6.5K | #4,483,848 | View details | |
| apcerls.com | 98% | – | #3,323,878 | View details | |
mt-pharma-america.com | mt-pharma-america.com | 96% | – | #11,554,805 | – |
| fortressbiotech.com | 92% | 11.6K | #2,326,761 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 15 similar websites and full traffic analytics for BrainStorm Cell
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 15 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Cell Therapy
10 companies that operate in the same segment as BrainStorm Cell (Cell Therapy), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 233 | |
T-cell-based immunotherapies for cancer treatment are developed. | 2000 | Tubingen, Baden-wurttemberg, Germany | USD 236.4 M | USD 54.47 M | 423 | |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases. | 2015 | London, England, United Kingdom | USD 181.37 M | USD 75.56 M | 647 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 253 | |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment | 2015 | Cambridge, Massachusetts, United States | USD 158 M | – | 58 | |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | 2011 | San Francisco, California, United States | USD 36.13 M | – | 36 | |
Developer of immune cell therapies | 2019 | San Francisco, California, United States | USD 631.16 M | – | 178 | |
Cue Biopharma is focused on developing immunotherapy solutions. | 2015 | Cambridge, Massachusetts, United States | USD 10 M | USD 27.47 M | 41 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Brainstorm Cell
Complete news archive for BrainStorm Cell
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BrainStorm Cell
BrainStorm Cell was founded in 2000 and raised its 1st funding round 12 years after it was founded.
BrainStorm Cell is headquartered in Petah Tikva, Israel. It is registered at Petah Tikva, Central District, Israel.
Chaim Lebovits is the current CEO of BrainStorm Cell.
BrainStorm Cell has 27 employees.
BrainStorm Cell Therapeutics was founded in 2000 in Petah Tikva, Israel, within the biotechnology sector. Autologous stem cell therapies are developed for neurodegenerative disorders such as ALS, multiple sclerosis, and Parkinsons disease. The NurOwn platform is utilized to differentiate mesenchymal stem cells into neurotrophic factor-secreting cells for transplantation near affected sites. Animal models of these diseases, including Huntingtons and peripheral nerve injury, are employed in research and testing.
BrainStorm Cell's top competitors include RoosterBio, Mesoblast and SanBio.
BrainStorm Cell offers NurOwn.
Yes, BrainStorm Cell is publicly traded on OTC under the ticker symbol BCLI.
BrainStorm Cell has 5 investors. Key investors include National MS Society, Israel Innovation Authority, I AM ALS, ALS Association, and Portalsaude.
BrainStorm Cell operates through Brainstorm Cell Therapeutics Inc..